Mesoblast completes Phase 3 low back pain trial treatment as pivotal readout approaches
Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial for chronic low back pain, with results expected in mid-2027.
Market Cap $1.937M
!
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Announcements
Filter Results
| TFL | AGM Voting Form | 20/04/18 | ||
| TFL | Notice of Annual General Meeting | 20/04/18 | ||
| TFL | TFL AGM Date | 29/03/18 | ||
| TFL | Appendix 3Z - Antony Robinson | 19/03/18 | ||
| TFL | Appendix 3X - Alexander Beard | 19/03/18 | ||
| TFL | Director Appointment and Resignation | 13/03/18 | ||
| TFL | Minor error in Annual Report | 28/02/18 | ||
| TFL | FY2017 Results Announcement | 27/02/18 | ||
| TFL | Appendix 4G | 27/02/18 | ||
| TFL | Corporate Governance Statement | 27/02/18 | ||
| TFL | Annual Report to shareholders | 27/02/18 | ||
| TFL | Preliminary Final Report | PRICE SENSITIVE | 27/02/18 | |
| TFL AGM Voting Form | |||
| 20/04/18 | |||
| TFL Notice of Annual General Meeting | |||
| 20/04/18 | |||
| TFL TFL AGM Date | |||
| 29/03/18 | |||
| TFL Appendix 3Z - Antony Robinson | |||
| 19/03/18 | |||
| TFL Appendix 3X - Alexander Beard | |||
| 19/03/18 | |||
| TFL Director Appointment and Resignation | |||
| 13/03/18 | |||
| TFL Minor error in Annual Report | |||
| 28/02/18 | |||
| TFL FY2017 Results Announcement | |||
| 27/02/18 | |||
| TFL Appendix 4G | |||
| 27/02/18 | |||
| TFL Corporate Governance Statement | |||
| 27/02/18 | |||
| TFL Annual Report to shareholders | |||
| 27/02/18 | |||
| TFL Preliminary Final Report | |||
| 27/02/18 | PRICE SENSITIVE | ||
